Trial Profile
A Phase I Dose Finding Study of XRP6258 Administered as a Weekly 1-hour Intravenous Infusion to Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 May 2015
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Cabazitaxel (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Sanofi
- 01 May 2015 New trial record